Compare CELU & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | UG |
|---|---|---|
| Founded | 2016 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 27.7M |
| IPO Year | N/A | N/A |
| Metric | CELU | UG |
|---|---|---|
| Price | $1.24 | $6.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 85.8K | 11.6K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 11.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $40,578,000.00 | $10,060,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | ★ N/A | $14.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $5.58 |
| 52 Week High | $4.35 | $11.98 |
| Indicator | CELU | UG |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 57.31 |
| Support Level | $1.20 | $6.08 |
| Resistance Level | $1.31 | $6.21 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 52.13 | 100.00 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.